David Tetrick
Internal Medicine · Noblesville, INNPI 1639183874
Payments from drug & device makers
Across 82 payments — averaging $72.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diabetes Care, Inc.$4K
- Novo Nordisk$280
- AstraZeneca$215
- Lilly USA, LLC$214
- Sun Pharmaceutical Industries Inc.$191
- Otsuka America Pharmaceutical, Inc.$185
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$3,78063%
- Food & beverage$2,18137%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diabetes Care, Inc. | 1 | $3,780 |
| Novo Nordisk | 13 | $280 |
| AstraZeneca | 7 | $215 |
| Lilly USA, LLC | 6 | $214 |
| Sun Pharmaceutical Industries Inc. | 4 | $191 |
| Otsuka America Pharmaceutical, Inc. | 4 | $185 |
| AbbVie(2 entities) | 8 | $144 |
| Amarin Pharma, Inc. | 3 | $138 |
| GSK | 1 | $116 |
| Amgen | 6 | $104 |
| Sunovion Pharmaceuticals Inc. | 1 | $80 |
| Pfizer | 5 | $75 |
| Acadia Pharmaceuticals Inc | 3 | $68 |
| Astellas Pharma US Inc | 3 | $61 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Novartis | 2 | $32 |
| Exact Sciences | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Lundbeck LLC | 1 | $29 |
| Boehringer Ingelheim | 1 | $25 |
| Eisai Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Shire North American Group Inc | 1 | $15 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,961 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 494 | $213,302 |
| XareltoRivaroxaban | 165 | $117,185 |
| OzempicSemaglutide | 42 | $66,727 |
| JardianceEmpagliflozin | 63 | $42,356 |
| FarxigaDapagliflozin Propanediol | 71 | $32,993 |
| JanuviaSitagliptin Phosphate | 19 | $28,521 |
| TrulicityDulaglutide | 28 | $27,368 |
| TradjentaLinagliptin | 63 | $26,764 |
| MounjaroTirzepatide | 23 | $25,894 |
| MyrbetriqMirabegron | 71 | $24,848 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $23,839 |
| SantylCollagenase Clostridium Hist. | 14 | $23,403 |
| GemtesaVibegron | 57 | $22,014 |
| RybelsusSemaglutide | 13 | $19,579 |
| EntrestoSacubitril/Valsartan | 42 | $18,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $75 | $220,207516 claims |
| Novo NordiskOzempic, Rybelsus | $280 | $86,30655 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $25 | $77,061142 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta | $116 | $65,376117 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $214 | $60,776140 claims |
| AstraZenecaFarxiga, Lokelma | $215 | $47,542105 claims |
| Astellas Pharma US IncMyrbetriq | $61 | $24,84871 claims |
| NovartisEntresto | $32 | $18,34042 claims |
| AbbVieLinzess | $144 | $7,35111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Noblesville
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.